About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Nanotalks
NBTXR3 Development
Head & Neck Cancer
R&D Day
Congresses
& Events
Our Expert Videos
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Corporate | Nanobiotix: 2017 review and 2018 expected milestones
26 December 2017
Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at American Society Of Clinical Oncology Gastrointestinal Annual Meeting
22 January 2018
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Published by
adminvl
on
11 January 2018
No translations available for this page
